ClinicalTrials.gg
Active, not recruitingNCT07275060Updated Jan 16, 2026

Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart

A Phase 4 interventional study of H5N1 vaccine (Arepanrix) and Saline (as a placebo) in H5N1 Influenza, H5N1 Virus and Avian Influenza, sponsored by Canadian Immunization Research Network. Active, not recruiting at 4 sites in Canada. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Canadian Immunization Research Network · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

Given the recent circulation of avian influenza A(H5N1) clade 2.3.4.4b strains in birds and mammals in North America, Canada procured a supply of Arepanrix™ H5N1 for potential use in persons at high risk of highly pathogenic avian influenza exposure.

This vaccine received regulatory approval in 2013, to be given in two doses at least 3 weeks apart. There is limited data on the effect of various intervals between the two doses on immunogenicity and tolerability. In this study two intervals between doses will be compared (3 vs. 8 weeks apart).

02

Conditions studied

  • H5N1 Influenza
  • H5N1 Virus
  • Avian Influenza
  • Avian Influenza A Virus

Browse trials for

Keywords

  • clinical trial
  • avian flu
  • H5N1
  • vaccine
03

In context

Influenza in Birds

96 studies on the registry are indexed under Influenza in Birds; 2 are open to participants now.

This study's planned enrollment of 312 is above the median of 150 across 88 interventional studies indexed under Influenza in Birds.

Browse Influenza in Birds studies →

Lead sponsor

Canadian Immunization Research Network is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals in stable health (defined as no new onset or exacerbation of pre-existing chronic disease three months prior to vaccination) 18-59 years of age.
  2. Able to comply with the trial procedures.
  3. signed prior to trial-specific procedures.
  4. If a person is at risk of becoming pregnant, has practiced adequate for 28 days prior to visit 1, and has a negative pregnancy test on the day of vaccination and has agreed to continue adequate contraception until 60 days after the final vaccination.

Risk of pregnancy is defined as any cis woman and/or gender divergent individual assigned female at birth or with reproductive capacity who is sexually active with individuals with sperm-producing capabilities.

Individual who are or permanently sterile (hysterectomy, bilateral salpingectomy) are not considered at risk of pregnancy. A post-menopausal state is defined as a no menses for 12 months.

Effective contraception methods are:

  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

    • Oral
    • Intravaginal
    • Transdermal
  • Progestogen-only hormonal contraception associated with inhibition of ovulation:

    • Oral
    • Injectable
    • Implantable
  • Intra-uterine device (IUD) with or without hormonal release.
  • Vasectomised partner, provided that this partner is your sole sexual partner and that the vasectomised partner has received a medical assessment of the surgical success.
  • Credible self-reported history of heterosexual abstinence prior to and for at least 28 days after the vaccine.

Effective contraception methods are:

  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

    • Oral
    • Intravaginal
    • Transdermal
  • Progestogen-only hormonal contraception associated with inhibition of ovulation:

    • Oral
    • Injectable
    • Implantable
  • Intra-uterine device (IUD) with or without hormonal release.
  • Vasectomised partner, provided that this partner is your sole sexual partner and that the vasectomised partner has received a medical assessment of the surgical success.
  • Credible self-reported history of heterosexual abstinence prior to and for at least 28 days after the vaccine.

Exclusion criteria

Exclusion Criteria:

  • Any of the following:

    1. Receipt of avian influenza A(H5N1) vaccine anytime.
    2. Positive pregnancy test prior to vaccination, or breastfeeding.
    3. Receipt of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine (except Rho D).
    4. Bleeding disorder or history of significant bleeding following IM injections or venipuncture.
    5. Any confirmed or suspected or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral (≤14 days duration) or topical steroids.
    6. A significant acute disease or temperature ≥38 Co within 24 hours prior to vaccination (temporary exclusion criteria, participants can return for evaluation to be randomized/ vaccinated 72 hours after symptoms resolve).
    7. Unstable chronic medical condition requiring ongoing follow-up and monitoring by a physician as determined by the investigator.
    8. History of anaphylaxis or allergy to any of the constituents or trace residues of the study vaccine, including egg protein.
    9. Receipt of non-study vaccine(s) 2 weeks prior to the study vaccine or planned 2 weeks after administration of the study vaccine.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (estimated)

Study arms

  • Active comparator
    Group 1: H5N1 vaccines administered 3 weeks apart

    Two doses of the H5N1 vaccine administered 3 weeks apart. Normal saline will be administered as a placebo at week 8.

    Biological: H5N1 vaccine (Arepanrix) · Other: Saline (as a placebo)

  • Active comparator
    Group 2: H5N1 vaccines administered 8 weeks apart

    Two doses of the H5N1 vaccine administered 8 weeks apart Normal saline will be administered as a placebo at week 3.

    Biological: H5N1 vaccine (Arepanrix) · Other: Saline (as a placebo)

Interventions

  • BiologicalArepanrixStudies of ArepanrixArepanrix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The H5N1 (Arepanrix) vaccine will be administered according to the Product Monograph.

    Also known as: Arepanrix, GSK

  • OtherSaline (as a placebo)

    Normal saline will be administered as a placebo according to the Product Monograph.

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. Percentages of participants with seroprotection against the H5N1 2.3.4.4b clade vaccine given 3 vs. 8 weeks apart

    Percentages of participants with seroprotection against the H5N1 2.3.4.4b clade 28 days following administration of 2 doses of avian influenza A(H5N1) vaccine given 3 vs. 8 weeks apart based on serologic outcomes at visit 4 (approximately week 12). Seroprotection is defined as the proportion of subjects who were either seronegative prior to vaccination and have a protective post-vaccination HI titre of ≥ 1:40 or who were seropositive prior to vaccination and have at least a 4-fold increase in HI titre post-vaccination.

    Time frame: 28 days post-administration of 2 doses of avian influenza A (H5N1 (Approximately week 12).

Secondary outcomes

  1. Immunogenicity - Percentages of participants with seroconversion and the geometric mean fold rise against the H5N1 2.3.4.4b clade vaccine given 3 vs. 8 weeks apart.

    Definition of Seroconversion rate: the proportion of subjects who were either seronegative prior to vaccination and have a protective post-vaccination HI titre of ≥ 1:40 or who were seropositive prior to vaccination and have at least a 4-fold increase in HI titre post-vaccination) as acceptable by regulators for approval of a Pandemic influenza Vaccine (22). Definition of Geometric mean fold rise: the ratio of the post-vaccination geometric mean HI titre divided by the pre-vaccination geometric mean HI titre) acceptable by regulators for approval of a Pandemic influenza Vaccine (22).

    Time frame: 28 days post-administration of 2 doses of avian influenza A (H5N1)

  2. Immunogenicity - GMT of HI against the H5N1 2.3.4.4b clade vaccine given 3 vs. 8 weeks apart.

    GMT of HI against the H5N1 2.3.4.4b clade 28 days following administration of 2 doses of avian influenza A(H5N1) vaccine given 3 vs. 8 weeks apart.

    Time frame: 28 days post-administration of 2 doses of avian influenza A (H5N1) vaccine

  3. Immunogenicity - Percentages of participants with seroprotection, seroconversion and the geometric mean fold rise against the H5N1 2.3.4.4b clade

    Percentages of participants with seroprotection, seroconversion and the geometric mean fold rise against the H5N1 2.3.4.4b clade following administration of 1 dose of avian influenza A(H5N1) vaccine.

    Time frame: at baseline, at 3 weeks, at 8 weeks, 12 weeks, 26 weeks and through study completion (average of 1 year).

  4. Immunogenicity - Percentages of participants with seroprotection, seroconversion and the geometric mean fold rise against the H5N1 2.3.4.4b clade

    Percentages of participants with seroprotection, seroconversion and the geometric mean fold rise against the H5N1 2.3.4.4b clade 6 and 12 months after the first dose of avian influenza A(H5N1) vaccine given 3 vs. 8 weeks apart.

    Time frame: 6 and 12 months after the first dose of avian influenza A (H5N1) vaccine

  5. Incidence of Grade 3 & 4 Adverse Events

    The following AEFIs will be collected in all participants: 1. Grade 3 solicited local and systemic adverse events in the 7 days following vaccine receipt; 2. SAEs at any time after vaccine receipt during the study; 3. MAAE at any time after vaccine receipt during the study, 4. AESI at any time after vaccine receipt during the study; 5. Provincially reportable AEFI at after vaccine receipt; and 6. acceptability as measured by participant questionnaire. Solicited adverse events and grading Grade 3 and 4 solicited local (injection-site) and systemic adverse events occurring during the 7-day follow-up period after each injection will be recorded. Solicited local (injection-site) adverse events (Pain, redness and swelling at injection site). Solicited systemic AEs, grade 3 and 4 will be recorded (Fatigue, fever - recorded, headache, nausea, diarrhea, vomiting, generalized muscle aches, joint pain and chills).

    Time frame: Up to 12 months after the first dose of avian influenza A (H5N1) vaccine

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Dec 10, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Sep 30, 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275060
Lead sponsor
Canadian Immunization Research Network
Collaborators
Dalhousie University, IWK Health Centre, Public Health Agency of Canada (PHAC), Canadian Center for Vaccinology, CHU de Quebec-Universite Laval, Vaccine Evaluation Center, Canada, McGill University Health Centre/Research Institute of the McGill University Health Centre
Responsible party
Joanne Langley (Principal Investigator, Canadian Immunization Research Network) — Principal investigator
First posted
Dec 10, 2025
Start date
Oct 14, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Joanne M Langley
principal investigator · CIRN, Canadian Center for Vaccinology, Dalhousie University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arepanrix

Start the discussion